TY  - JOUR
AU  - Martín, M
AU  - Chan, A
AU  - Dirix, L
AU  - O'Shaughnessy, J
AU  - Hegg, R
AU  - Manikhas, A
AU  - Shtivelband, M
AU  - Krivorotko, P
AU  - Batista López, N
AU  - Campone, M
AU  - Ruiz Borrego, M
AU  - Khan, Q J
AU  - Beck, J T
AU  - Ramos Vázquez, M
AU  - Urban, P
AU  - Goteti, S
AU  - Di Tomaso, E
AU  - Massacesi, C
AU  - Delaloge, S
PY  - 2017
DO  - 10.1093/annonc/mdw562
UR  - http://hdl.handle.net/10668/10569
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120)...
LA  - en
KW  - HER2−
KW  - PI3K pathway
KW  - advanced breast cancer
KW  - breast cancer
KW  - buparlisib (BKM120)
KW  - paclitaxel
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Morpholines
KW  - Paclitaxel
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Proportional Hazards Models
KW  - Receptor, ErbB-2
KW  - Treatment Outcome
KW  - Young Adult
TI  - A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
TY  - research article
VL  - 28
ER  -